PNAS 上的研究表明，更广泛地获得 semaglutide 等减肥药物可以防止 42,000+ 美国人死亡并降低肥胖率，并带来额外的健康益处。 Study in PNAS suggests broader access to weight loss drugs like semaglutide could prevent 42,000+ U.S. deaths and lower obesity rates, with additional health benefits.
PNAS的一项研究表明,更广泛地获得减重药物,特别是GLP-1型受体激动剂,如西马格卢特,通过解决影响42%成年人的肥胖问题,每年可以预防42 000多例美国死亡。 A study in PNAS indicates that broader access to weight loss drugs, particularly GLP-1 receptor agonists like semaglutide, could prevent over 42,000 U.S. deaths annually by addressing obesity, which affects 42% of adults. 如果普及,肥胖率可以降低到38%,防止另外50 000人死亡。 If universally accessible, obesity rates could drop to 38%, preventing an additional 50,000 deaths. 这些药物还显示出对心血管健康、肾功能和潜在的心理健康改善的好处,表明肥胖症治疗有所转变。 These drugs also show benefits for cardiovascular health, kidney function, and potential mental health improvements, signaling a shift in obesity treatment.